Flavopiridol in Treating Patients With Previously Untreated or Relapsed Mantle Cell Lymphoma

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically or cytologically confirmed mantle cell lymphoma (at initial diagnosis) nonrefractory to prior therapy or with no prior therapy
• * No documented disease progression while receiving prior chemotherapy
• CD20 and CD5 positive
• Presence of clinically and/or radiologically documented disease
• At least 1 site of disease must be bidimensionally measurable
• * Bone lesions not considered bidimensionally measurable
• * Minimum indicator lesions must be:
• * Lymph nodes at least 1.5 cm x 1.5 cm by physical exam or spiral CT scan OR
• * Other nonnodal lesions at least 1 cm x 1 cm by MRI, CT scan, or physical exam
• No known CNS involvement by lymphoma
• PATIENT CHARACTERISTICS:
• Age:
• 18 and over
• Performance status:
• ECOG 0-2
• Life expectancy:
• At least 12 weeks
• Hematopoietic:
• Absolute granulocyte count at least 1,500/mm3
• Platelet count at least 75,000/mm3
• Hepatic:
• Bilirubin no greater than 1.5 times upper limit or normal (ULN)
• AST no greater than 2.5 times ULN
• Renal:
• Creatinine no greater than 1.5 times ULN OR
• Creatinine clearance at least 60 mL/min
• Cardiovascular:
• No clinically significant cardiac symptomatology
• If history of cardiac disease, cardiac ejection fraction greater than 50%
• Pulmonary:
• No clinically significant pulmonary symptomatology
• If history of symptomatic pulmonary disease:
• * FEV1, FVC, and TLC greater than 60% predicted
• * DLCO greater than 50% predicted
• Other:
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• Must be accessible for treatment and follow-up (i.e., no geographical limitations)
• No uncontrolled bacterial, fungal, or viral infection
• No other serious concurrent disease
• PRIOR CONCURRENT THERAPY:
• Biologic therapy:
• No prior radioactive monoclonal antibody therapy
• Prior rituximab allowed
• Chemotherapy:
• See Disease Characteristics
• No more than 2 prior chemotherapy regimens allowed
• Same chemotherapy combination given for first line and second line therapy considered 2 regimens
• At least 6 weeks since prior chemotherapy
• No prior high-dose chemotherapy and stem cell transplantation
• No other concurrent cytotoxic chemotherapy
• Endocrine therapy:
• No concurrent corticosteroids
• Radiotherapy:
• No prior radiotherapy to greater than 25% of functioning bone marrow
• At least 4 weeks since prior radiotherapy (except low-dose, non-myelosuppressive radiotherapy) and recovered
• No concurrent radiotherapy to sole site of measurable disease
• Surgery:
• At least 2 weeks since prior major surgery
• Other:
• No other concurrent investigational anticancer agents